These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27761962)

  • 1. European retrospective study of real-life haemophilia treatment.
    Berntorp E; Dolan G; Hay C; Linari S; Santagostino E; Tosetto A; Castaman G; Álvarez-Román MT; Parra Lopez R; Oldenburg J; Albert T; Scholz U; Holmström M; Schved JF; Trossaërt M; Hermans C; Boban A; Ludlam C; Lethagen S
    Haemophilia; 2017 Jan; 23(1):105-114. PubMed ID: 27761962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B.
    Mason JA; Parikh S; Tran H; Rowell J; McRae S
    Haemophilia; 2018 Mar; 24(2):253-260. PubMed ID: 29314552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose continuous infusion of factor VIII in patients with haemophilia A.
    Prelog T; Dolničar MB; Kitanovski L
    Blood Transfus; 2016 Sep; 14(5):474-80. PubMed ID: 26674820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K; Walker I; Decker K; Chan AK; Pai MK
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.
    Funding E; Lowe G; Poulsen LH; Shapiro S; Oldenburg J; Eriksson D; Falk A; Rich C
    Adv Ther; 2023 Sep; 40(9):3770-3783. PubMed ID: 37351812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Haemophilia A and haemophilia B. Are there relevant clinical differences?].
    Klamroth R; Orlovic M; Kubicek-Hofman C; Gottstein S
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S26-7. PubMed ID: 21042678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey.
    Abbonizio F; Hassan HJ; Riccioni R; Santagostino E; Arcieri R; Giampaolo A;
    Blood Transfus; 2020 Jan; 18(1):58-66. PubMed ID: 30865582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
    Kruse-Jarres R; Oldenburg J; Santagostino E; Shima M; Kempton CL; Kessler CM; Lehle M; Chebon S; Selak Bienz N; Asikanius E; Mahlangu J
    Haemophilia; 2019 Mar; 25(2):213-220. PubMed ID: 30724422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term analysis of the benefit of prophylaxis for adult patients with severe or moderate haemophilia A.
    Miesbach W; Kittler S; Bauhofer A; Königs C; Becker T; Nemes L; Staus A; Schüttrumpf J
    Haemophilia; 2020 May; 26(3):467-477. PubMed ID: 32293085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B - The MoHem study.
    Måseide RJ; Berntorp E; Astermark J; Olsson A; Bruzelius M; Frisk T; Nummi V; Lassila R; Tjønnfjord GE; Holme PA
    Haemophilia; 2020 Sep; 26(5):891-897. PubMed ID: 33021747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
    Iorio A; Königs C; Reding MT; Rotellini D; Skinner MW; Mancuso ME; Berntorp E
    Haemophilia; 2023 Jan; 29(1):33-44. PubMed ID: 36224704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B.
    Booth J; Oladapo A; Walsh S; O'Hara J; Carroll L; Garcia Diego DA; O'Mahony B
    Haemophilia; 2018 Sep; 24(5):e322-e327. PubMed ID: 30091822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemophilia care in Europe: the ESCHQoL study.
    Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
    Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe.
    Burke T; Asghar S; O'Hara J; Chuang M; Sawyer EK; Li N
    Orphanet J Rare Dis; 2021 Dec; 16(1):521. PubMed ID: 34930388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Haemophilia A, B or von Willebrand disease type 3. Census of patients in the eastern part of Germany].
    Scholz U; Syrbe G; Koscielny J; Klamroth R;
    Hamostaseologie; 2008; 28(3):150-4. PubMed ID: 18521493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.